<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5630974</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx163.1861</article-id><article-id pub-id-type="publisher-id">ofx163.1861</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Poster Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>Single Dose IV Peramivir is Safe and Effective in the Treatment of Pediatric Influenza</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Vanchiere</surname><given-names>John</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Plunkett</surname><given-names>Stephanie</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Annamalai</surname><given-names>Rajasekaran</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Julien</surname><given-names>Katie</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Peterson</surname><given-names>James</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Goisse</surname><given-names>Marcy</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Christensen</surname><given-names>Shane</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Mehta</surname><given-names>Priyesh</given-names></name><degrees>DO</degrees><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>Coleman</surname><given-names>Stephen</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0008">8</xref></contrib><contrib contrib-type="author"><name><surname>Munoz</surname><given-names>Flor</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0009">9</xref></contrib><contrib contrib-type="author"><name><surname>Flynt</surname><given-names>Amy</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0010">10</xref></contrib><contrib contrib-type="author"><name><surname>Dobo</surname><given-names>Sylvia</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0011">11</xref></contrib><contrib contrib-type="author"><name><surname>Nagy</surname><given-names>Eniko</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0011">11</xref></contrib><contrib contrib-type="author"><name><surname>Kargl</surname><given-names>Deborah</given-names></name><degrees>BSc</degrees><xref ref-type="aff" rid="AF0011">11</xref></contrib><contrib contrib-type="author"><name><surname>Mathis</surname><given-names>Amanda</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0012">12</xref></contrib><contrib contrib-type="author"><name><surname>Collis</surname><given-names>Phil</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0011">11</xref></contrib><contrib contrib-type="author"><name><surname>Sheridan</surname><given-names>William</given-names></name><degrees>MB BS</degrees><xref ref-type="aff" rid="AF0012">12</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>Pediatrics, LSUHSC-Shreveport</institution>, <addr-line>Shreveport, Louisiana</addr-line></aff><aff id="AF0002">
<label>2</label>
<institution>J Lewis Research</institution>, <addr-line>Salt Lake City, Utah</addr-line></aff><aff id="AF0003">
<label>3</label>
<institution>East Montgomery County Clinic</institution>, <addr-line>Splendora, Texas</addr-line></aff><aff id="AF0004">
<label>4</label>
<institution>J Lewis Research</institution>, <addr-line>South Jordan, Utah</addr-line></aff><aff id="AF0005">
<label>5</label>
<institution>Montgomery Medical</institution>, <addr-line>Smithfield, Pennsylvania</addr-line></aff><aff id="AF0006">
<label>6</label>
<institution>J. Lewis Research</institution>, <addr-line>Salt Lake City, Utah</addr-line></aff><aff id="AF0007">
<label>7</label>
<institution>DOC Clinical Research</institution>, <addr-line>Dayton, Ohio</addr-line></aff><aff id="AF0008">
<label>8</label>
<institution>J Lewis Research</institution>, <addr-line>Draper, Utah</addr-line></aff><aff id="AF0009">
<label>9</label>
<institution>Pediatric Infectious Diseases, Baylor College of Medicine, Texas Children&#x02019;s Hospital</institution>, <addr-line>Houston, Texas</addr-line></aff><aff id="AF0010">
<label>10</label>
<institution>PharPoint Research</institution>, <addr-line>Wilmington, North Carolina</addr-line></aff><aff id="AF0011">
<label>11</label>
<institution>BioCryst Pharmaceuticals</institution>, <addr-line>Durham, North Carolina</addr-line></aff><aff id="AF0012">
<label>12</label>
<institution>BioCryst Pharmaceuticals Inc.</institution>, <addr-line>Durham, North Carolina</addr-line></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 252. Pediatric Virology</p><p>
<italic>Saturday, October 7, 2017: 12:30 PM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S694</fpage><lpage>S694</lpage><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx163.1861.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>Peramivir (PVR) is a potent neuraminidase inhibitor with <italic>in vitro</italic> activity against all influenza virus subtypes. Previous studies demonstrated the efficacy and safety of PVR as a single dose intravenous (IV) treatment for acute uncomplicated influenza in adults.</p></sec><sec id="s2"><title>Methods</title><p>A phase 3 study compared age-appropriate doses of single dose IV PVR to 5&#x000a0;days of oral oseltamivir (OSE) (4:1 randomization, stratified by age) in pediatric subjects age 0 -17&#x000a0;years within 48 hours of onset of acute uncomplicated influenza. Plasma concentrations of PVR were measured up to 6 hours post dose. Serial viral titers were measured from nasopharyngeal swabs. Severity of influenza signs and symptoms were recorded in a&#x000a0;diary.</p></sec><sec id="s3"><title>Results</title><p>122 subjects were enrolled up to a data cutoff of March 31, 2017 (&#x0003c;2 yrs, <italic>n =</italic> 7; 2-&#x0003c;7yrs, <italic>n =</italic> 37; 7-&#x0003c;13 yrs, <italic>n =</italic> 48; 13&#x02013;17 yrs, <italic>n =</italic> 30). Interim results are reported for the first 108 subjects randomized, of which 101 (94%) received study drug. Influenza was confirmed by PCR in 75 (74%) subjects who received study drug (Intent-to-treat-Infected [ITTI] population). Key endpoints are summarized:</p><table-wrap id="T1" orientation="portrait" position="float"><table frame="box" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">PVR</th><th align="center" valign="bottom" rowspan="1" colspan="1">OSE</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Intent to treat (ITT) population: n (all age groups)</td><td align="center" valign="bottom" rowspan="1" colspan="1">85</td><td align="center" valign="bottom" rowspan="1" colspan="1">23</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">ITTI population: n (%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">59</td><td align="center" valign="bottom" rowspan="1" colspan="1">16</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">A/H1N1</td><td align="center" valign="bottom" rowspan="1" colspan="1">22 (37%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">9 (56%)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">A/H3N2</td><td align="center" valign="bottom" rowspan="1" colspan="1">12 (20%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">3 (19%)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">A/Ind</td><td align="center" valign="bottom" rowspan="1" colspan="1">1 (2%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">B</td><td align="center" valign="bottom" rowspan="1" colspan="1">23 (39%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">4 (25%)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">A + B</td><td align="center" valign="bottom" rowspan="1" colspan="1">1 (2%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Proportion of ITTI population shedding virus<sup>1</sup>, n (%)</td><td align="center" valign="bottom" rowspan="1" colspan="1"/><td align="center" valign="bottom" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Baseline</td><td align="center" valign="bottom" rowspan="1" colspan="1">53/59 (90%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">14/16 (88%)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Day 3</td><td align="center" valign="bottom" rowspan="1" colspan="1">27/59 (46%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">10/16 (63%)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Day 7</td><td align="center" valign="bottom" rowspan="1" colspan="1">2/59 (3%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0/16 (0%)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Day 14</td><td align="center" valign="bottom" rowspan="1" colspan="1">0/59 (0%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0/16 (0%)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Time to alleviation of symptoms, hrs<sup>2</sup></td><td align="center" valign="bottom" rowspan="1" colspan="1">75.6 (47.0, 109.2)</td><td align="center" valign="bottom" rowspan="1" colspan="1">99.8 (34.7, 133.6)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Time to resolution of fever, hrs<sup>2</sup></td><td align="center" valign="bottom" rowspan="1" colspan="1">40.5 (22.1, 47.0)</td><td align="center" valign="bottom" rowspan="1" colspan="1">34.7 (13.7, 42.3)</td></tr></tbody></table><table-wrap-foot><fn id="fn0009"><p>
<sup>1</sup>Determined by virus culture assay; <sup>2</sup>ITTI population: median (95% CI).</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><caption><p>No serious adverse events were reported. AEs occurring in more than two subjects overall were:</p></caption><table frame="box" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">PVR</th><th align="center" valign="bottom" rowspan="1" colspan="1">OSE</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Safety population: n</td><td align="center" valign="bottom" rowspan="1" colspan="1">78</td><td align="center" valign="bottom" rowspan="1" colspan="1">23</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Any event</td><td align="center" valign="bottom" rowspan="1" colspan="1">17 (22%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">5 (22%)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Vomiting</td><td align="center" valign="bottom" rowspan="1" colspan="1">2 (3%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2 (9%)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Nausea</td><td align="center" valign="bottom" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2 (9%)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Pyrexia</td><td align="center" valign="bottom" rowspan="1" colspan="1">2 (3%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Tympanic membrane hyperemia</td><td align="center" valign="bottom" rowspan="1" colspan="1">2 (3%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0 (0%)</td></tr></tbody></table></table-wrap></sec><sec id="s69"><title>Conclusion</title><p>Treatment of influenza in pediatric subjects with single dose IV PVR or 5&#x000a0;days of oral OSE was generally safe and well tolerated. Whilst not powered for efficacy differences, trends were observed in more rapid reduction in virus shedding and symptom alleviation for PVR treated subjects compared with OSE. The study continues to enroll subjects &#x0003c; 7&#x000a0;years.</p></sec><sec id="s5"><title>Disclosures</title><p>
<bold>J. Vanchiere</bold>, BioCryst Pharmaceuticals: Consultant and Investigator, Consulting fee and Research support; <bold>S. Plunkett</bold>, BioCryst Pharmaceuticals: Investigator, Research support; <bold>R. Annamalai</bold>, BioCryst Pharmaceuticals: Investigator, Research support; <bold>K. Julien</bold>, BioCryst Pharmaceuticals: Investigator, Research support; <bold>J. Peterson</bold>, BioCryst Pharmaceuticals: Investigator, Research support; <bold>M. Goisse</bold>, BioCryst Pharmaceuticals: Investigator, Research support; <bold>S. Christensen</bold>, BioCryst Pharmaceuticals: Investigator, Research support; <bold>P. Mehta</bold>, BioCryst Pharmaceuticals: Investigator, Research support; <bold>S. Coleman</bold>, BioCryst Pharmaceuticals: Investigator, Research support; <bold>F. Munoz</bold>, BioCryst Pharmaceuticals: Investigator, Research support; <bold>A. Flynt</bold>, BioCryst Pharmaceuticals: Consultant, Consulting&#x000a0;fee; <bold>S. Dobo</bold>, BioCryst Pharmaceuticals: Employee,&#x000a0;Salary; <bold>E. Nagy</bold>, BioCryst Pharmaceuticals: Employee,&#x000a0;Salary; <bold>D. Kargl</bold>, BioCryst Pharmaceuticals: Consultant, Consulting&#x000a0;fee; <bold>A. Mathis</bold>, BioCryst Pharmaceuticals: Employee,&#x000a0;Salary; <bold>P. Collis</bold>, BioCryst Pharmaceuticals: Employee,&#x000a0;Salary; <bold>W. Sheridan</bold>, BioCryst Pharmaceuticals: Employee, Salary</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>